Oncolytic viruses: A novel form of immunotherapy

R. J D Prestwich, Kevin J. Harrington, Hardev S. Pandha, Richard Geoffrey Vile, Alan A. Melcher, Fiona Errington

Research output: Contribution to journalArticle

114 Citations (Scopus)

Abstract

Oncolytic viruses are novel anticancer agents, currently under investigation in Phase I-III clinical trials. Until recently, most studies have focused on the direct antitumor properties of these viruses, although there is now an increasing body of evidence that the host immune response may be critical to the efficacy of oncolytic virotherapy. This may be mediated via innate immune effectors, adaptive antiviral immune responses eliminating infected cells or adaptive antitumor immune responses. This report summarizes preclinical and clinical evidence for the importance of immune interactions, which may be finely balanced between viral and tumor elimination. On this basis, oncolytic viruses represent a promising novel immunotherapy strategy, which may be optimally combined with existing therapeutic modalities.

Original languageEnglish (US)
Pages (from-to)1581-1588
Number of pages8
JournalExpert Review of Anticancer Therapy
Volume8
Issue number10
DOIs
StatePublished - 2008

Fingerprint

Oncolytic Viruses
Adaptive Immunity
Immunotherapy
Oncolytic Virotherapy
Phase III Clinical Trials
Clinical Trials, Phase I
Antineoplastic Agents
Antiviral Agents
Viruses
Neoplasms
Therapeutics

Keywords

  • Adaptive
  • Clinical trial
  • Immune response
  • Immunotherapy
  • Innate
  • Oncolytic virus

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Prestwich, R. J. D., Harrington, K. J., Pandha, H. S., Vile, R. G., Melcher, A. A., & Errington, F. (2008). Oncolytic viruses: A novel form of immunotherapy. Expert Review of Anticancer Therapy, 8(10), 1581-1588. https://doi.org/10.1586/14737140.8.10.1581

Oncolytic viruses : A novel form of immunotherapy. / Prestwich, R. J D; Harrington, Kevin J.; Pandha, Hardev S.; Vile, Richard Geoffrey; Melcher, Alan A.; Errington, Fiona.

In: Expert Review of Anticancer Therapy, Vol. 8, No. 10, 2008, p. 1581-1588.

Research output: Contribution to journalArticle

Prestwich, RJD, Harrington, KJ, Pandha, HS, Vile, RG, Melcher, AA & Errington, F 2008, 'Oncolytic viruses: A novel form of immunotherapy', Expert Review of Anticancer Therapy, vol. 8, no. 10, pp. 1581-1588. https://doi.org/10.1586/14737140.8.10.1581
Prestwich RJD, Harrington KJ, Pandha HS, Vile RG, Melcher AA, Errington F. Oncolytic viruses: A novel form of immunotherapy. Expert Review of Anticancer Therapy. 2008;8(10):1581-1588. https://doi.org/10.1586/14737140.8.10.1581
Prestwich, R. J D ; Harrington, Kevin J. ; Pandha, Hardev S. ; Vile, Richard Geoffrey ; Melcher, Alan A. ; Errington, Fiona. / Oncolytic viruses : A novel form of immunotherapy. In: Expert Review of Anticancer Therapy. 2008 ; Vol. 8, No. 10. pp. 1581-1588.
@article{c6055a2d0f524b6d82ae446083551f64,
title = "Oncolytic viruses: A novel form of immunotherapy",
abstract = "Oncolytic viruses are novel anticancer agents, currently under investigation in Phase I-III clinical trials. Until recently, most studies have focused on the direct antitumor properties of these viruses, although there is now an increasing body of evidence that the host immune response may be critical to the efficacy of oncolytic virotherapy. This may be mediated via innate immune effectors, adaptive antiviral immune responses eliminating infected cells or adaptive antitumor immune responses. This report summarizes preclinical and clinical evidence for the importance of immune interactions, which may be finely balanced between viral and tumor elimination. On this basis, oncolytic viruses represent a promising novel immunotherapy strategy, which may be optimally combined with existing therapeutic modalities.",
keywords = "Adaptive, Clinical trial, Immune response, Immunotherapy, Innate, Oncolytic virus",
author = "Prestwich, {R. J D} and Harrington, {Kevin J.} and Pandha, {Hardev S.} and Vile, {Richard Geoffrey} and Melcher, {Alan A.} and Fiona Errington",
year = "2008",
doi = "10.1586/14737140.8.10.1581",
language = "English (US)",
volume = "8",
pages = "1581--1588",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "10",

}

TY - JOUR

T1 - Oncolytic viruses

T2 - A novel form of immunotherapy

AU - Prestwich, R. J D

AU - Harrington, Kevin J.

AU - Pandha, Hardev S.

AU - Vile, Richard Geoffrey

AU - Melcher, Alan A.

AU - Errington, Fiona

PY - 2008

Y1 - 2008

N2 - Oncolytic viruses are novel anticancer agents, currently under investigation in Phase I-III clinical trials. Until recently, most studies have focused on the direct antitumor properties of these viruses, although there is now an increasing body of evidence that the host immune response may be critical to the efficacy of oncolytic virotherapy. This may be mediated via innate immune effectors, adaptive antiviral immune responses eliminating infected cells or adaptive antitumor immune responses. This report summarizes preclinical and clinical evidence for the importance of immune interactions, which may be finely balanced between viral and tumor elimination. On this basis, oncolytic viruses represent a promising novel immunotherapy strategy, which may be optimally combined with existing therapeutic modalities.

AB - Oncolytic viruses are novel anticancer agents, currently under investigation in Phase I-III clinical trials. Until recently, most studies have focused on the direct antitumor properties of these viruses, although there is now an increasing body of evidence that the host immune response may be critical to the efficacy of oncolytic virotherapy. This may be mediated via innate immune effectors, adaptive antiviral immune responses eliminating infected cells or adaptive antitumor immune responses. This report summarizes preclinical and clinical evidence for the importance of immune interactions, which may be finely balanced between viral and tumor elimination. On this basis, oncolytic viruses represent a promising novel immunotherapy strategy, which may be optimally combined with existing therapeutic modalities.

KW - Adaptive

KW - Clinical trial

KW - Immune response

KW - Immunotherapy

KW - Innate

KW - Oncolytic virus

UR - http://www.scopus.com/inward/record.url?scp=55249101013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55249101013&partnerID=8YFLogxK

U2 - 10.1586/14737140.8.10.1581

DO - 10.1586/14737140.8.10.1581

M3 - Article

C2 - 18925850

AN - SCOPUS:55249101013

VL - 8

SP - 1581

EP - 1588

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 10

ER -